相关实验视频
Updated: Jun 20, 2026

07:48
Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
9.8K
审查报告的利益相关者参与早期翻译研究的参与情况
Thomas W Concannon1,2,3, Marguerite Fenwood Hughes3, Amy E LaVertu4
1The RAND Corporation, Boston, MA, USA.
Journal of clinical and translational science
|February 6, 2025
概括
关于利益相关者参与早期翻译研究的报告很少见. 这次范围审查突出了已发表文献中的差距,表明需要更好地记录社区参与研究的情况.
科学领域:
- 翻译科学 翻译科学
- 卫生研究 卫生研究 卫生研究
- 利益相关者参与 利益相关者参与
背景情况:
- 早期的翻译研究涉及多个利益相关者.
- 了解利益相关者的参与对于研究进展至关重要.
- 报告这种参与往往是有限的.
研究的目的:
- 描述有关利益相关者的参与报告的性质和范围.
- 识别早期翻译研究参与的文档上的差距.
主要方法:
- 对同行评审文献进行范围审查.
- 搜索了六个数据库,得到了2,894个记录.
- 在选后,包括了13篇文章.
主要成果:
- 发现了有关利益相关者参与的罕见报告.
- 与患者,临床医生和研究人员的接触是最常见的.
- 与政策制定者,行业和保险公司的接触较少被报道.
- 四分之一的文章只在感谢中提到参与.
- 超过一半的人对参与结果得出了未经测量的结论.
结论:
- 关于利益相关者参与早期翻译研究的重大报告缺口存在.
- 这种差距可能并非反映了缺乏实践,而是反映了文件不足.
- 解决诸如共享语言,框架,资源和研究议程等主题可以改善报告和洞察力.
相关概念视频
Improving Translational Accuracy
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
Improving Translational Accuracy
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Translational Regulation
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...

